|Bid||40.19 x 30000|
|Ask||41.18 x 30000|
|Day's Range||41.17 - 41.21|
|52 Week Range||12.76 - 42.94|
|Beta (3Y Monthly)||2.82|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Acadia Pharmaceuticals is the IBD Stock Of The Day as investors look ahead to a presentation of the biotech company's psychosis treatment, a drug known by the test name of pimavanserin.
We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, smart money investors have to conduct complex analyses, spend many resources and use tools that are not always […]
H.C. Wainwright & Co. analyst Andrew Fein reiterated a Buy rating on Acadia with a $60 price target. Acadia delivered another pleasant surprise for investors by way of a positive interim analysis from the Phase 3 HARMONY study, which showed pimavanserin's statistically superior efficacy compared to placebo in time to relapse of dementia-related psychosis, Fein said in a Tuesday note. The analyst sees the dementia-related psychosis opportunity alone as sufficient to fuel pimavanserin growth in the foreseeable future.
Shares of Acadia Pharmaceuticals rocketed Monday after the biotech company said its psychosis treatment met its key goal in a Phase 3 test. The drug already sells under the name Nuplazid.
Acadia, an actively traded mid-cap biotech, said Monday that it will stop the Phase 3 HARMONY study early based on the recommendation of the independent data monitoring committee that reviewed data from the planned interim analysis. The HARMONY study is evaluating pimavanserin for the treatment of dementia-related psychosis. Interim analysis of data showed the study met its primary endpoint by demonstrating a highly statistically significant longer time to the relapse of psychosis with pimavanserin compared to placebo.
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. ACADIA Pharmaceuticals (NASDAQ: ACAD ) shares ...
Acadia Pharmaceuticals rockets higher after it announces it has ended a phase 3 trial of its dementia-related psychosis treatment, pimavanserin, on better-than-expected results.
Shares of Acadia Pharmaceuticals Inc. rocketed 87% toward a 4-year high in premarket trading Monday, after the biopharmaceutical company said a phase 3 trial of its treatment for dementia-related psychosis met its primary endpoint. The company said pimavanserin achieved "robust statistical superiority" over placebo, with longer time to relapse of psychosis with pimavanserin compared with placebo. Acadia said the study will be stopped early based on the study's findings. The company plans to meet with the Food and Drug Administration regarding a supplemental new drug application (NDA) submission in 2020. The stock, on track to open at the highest price seen during regular-session hours since August 2015, has run up 47.2% year to date through Friday, while the iShares Nasdaq Biotechnology ETF has gained 6.0% and the S&P 500 has advanced 18.8%.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 22) Acasti Pharma Inc (NASDAQ: ACST ) Apellis Pharmaceuticals ...
In the study, 396 patients with moderate-to-severe psychotic symptoms were given Acadia's treatment pimavanserin or placebo as an add-on to their current antipsychotic treatment, the company said. Adding pimavanserin to existing antipsychotic treatment showed a consistent trend in improvement of psychotic symptoms, however, the results did not show statistical significance in achieving the main goal, Acadia said.
Stock drops as Pimavanserin study finds no statistically significant improvement in adult schizophrenia patients.
The pharma company was an easy target for Mr. Market during last month's sell-off, but it appears well positioned for a rebound in 2019.